Neurocrine Biosciences initiates trial of VMAT2 inhibitor in healthy adults
The therapy joins another VMAT2 inhibitor, NBI-1065890, which is undergoing assessment by the company in Phase I trials.
Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating NBI-1140675, a Second-Generation VMAT2 Inhibitor, in Healthy Adults
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the initiation of a Phase 1 clinical study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of investigational ...
Nasdaq6d
Neurocrine's Phase 4 Study Shows INGREZZA Improves Quality Of Life For Tardive Dyskinesia Patients
The company noted that the KINECT-PRO is the first study to show patient-reported impact of a vesicular monoamine transporter 2 inhibitor, specifically INGREZZA, on tardive dyskinesia or TD using ...
Neurocrine reports patient-reported outcome data from KINECT-PRO study
Biosciences announced top-line data from a Phase 4 study, KINECT-PRO, demonstrating clinically meaningful and sustained ...
WebMD3d
A Face of Tardive Dyskinesia
TD, or tardive dyskinesia, is pretty much uncontrollable, jerky movements of the body. Smacking of the lips, licking, or jaw movements. I have Tourette's, and I kind of feel like it's just an ...
The Pharma Letter6d
Phase IV Ingrezza data move focus from sales outlook
Neurocrine Biosciences (Nasdaq: NBIX) has announced positive results from its Phase IV KINECT-PRO study, showing that ...
Neurocrine begins Phase 1 clinical study of NBI-1140675
Biosciences announced the initiation of a Phase 1 clinical study to evaluate the safety, tolerability, pharmacokinetics and ...
pharmaphorum4d
Neurocrine achieves a first with tardive dyskinesia drug Ingrezza
The FDA has approved Neurocrine Bioscience’s Ingrezza, the first ever licensed treatment for tardive dyskinesia or TD. The condition is characterised by uncontrollable movement of the body or ...
Winston-Salem Journal2d
NC Medical Board suspends Triad-based psychiatrist's license
A psychiatrist with the Greensboro practice of Mood Treatment Centers has had his medical license indefinitely suspended indefinitely by the N.C. Medical Board. The board posted Monday the consent ord ...
Australia: Senior NSW psychiatrist condemns Labor’s assault on public sector mental health care
We’re trying to treat unstable and traumatised patients in a public mental health care system that has become unstable itself ...
Valley Advocate5d
What is possible when you get to the root?: The peer-run Wildflower Alliance redefines mental health care, leaves the system in the dust
By Melissa Karen Sances For the Valley Advocate Her phone pinged and a grey bubble rose to the surface: “Are you ready to ...
clinicaladvisor.com3d
Targeted AI Tools May Enhance Patient Care and Reduce Administrative Burdens in Family Medicine
For AI to improve efficiency, it must be developed with a clear focus on practical applications rather than unnecessary diagnostic tools and risk calculators. Artificial intelligence (AI) has the ...